Navigation Links
Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance
Date:8/7/2014

may be unable to achieve expected synergies and operating efficiencies in connection with the transaction within the expected time-frames or at all and to successfully integrate the Acquired Business; the Company's and the Acquired Business' expected or targeted future financial and operating performance and results; the Company's (prior to or after the close of the Transaction) capacity to bring new products to market, including but not limited to where the Company uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an "at-risk launch"); the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings on the Company's and the Acquired Business' consolidated financial condition, results of operations or cash flows; the ability to protect the intellectual property and preserve the intellectual property rights of the Company and the Acquired Business; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the Company's business or the Acquired Business; the inherent challenges, risks and costs in the Company's ability to identify, acquire and integrate complementary or strategic acquisitions of other companies, products or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with GAAP and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with the
'/>"/>
SOURCE Mylan Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the list ... the Zacks Equity Research analysts discuss the latest news ... recently featured in the blog include the Avanir Pharmaceuticals (Nasdaq: ... NPSP - Free Report ), Orexigen (Nasdaq: ... - Free Report ) and Gilead (Nasdaq: GILD ...
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4
... AGAWAM, Mass., June 7, 2011 A free white ... validation of their cleaning processes is available from Microtest ... . As many medical devices are made ... plastics, manufacturers may require the use of various agents ...
... Biomedical Inc., a developer of an advanced implantable vena cava ...  The round was led by Three Arch Partners, which was ... Vena cava filters, which were first introduced ... that can lead to a potentially fatal pulmonary embolism (PE). ...
Cached Medicine Technology:New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes 2Crux Successfully Completes Funding for Advanced Filter for PE Prevention 2
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 "Medical ... patient care while also maintaining the patient's privacy," said ... up with this idea in order to supply caregivers ... well." , They created a prototype for The Helper ... device enables staff to turn patient onto his or ...
(Date:9/18/2014)... 2014 Companies in the Carbon ... selling it to downstream industries in either gas, liquid ... are food and beverage manufacturers. Food producers use carbon ... or pizzas. The gas is also used as a ... to carbonate soft drinks, beer and other beverages. According ...
(Date:9/18/2014)... Daily supplements of selenium or vitamin E don,t seem ... among men, a new study indicates. Previous animal ... prevent cataracts. To investigate this further, William Christen, from ... Boston, and his colleagues examined data from a randomized, ... was initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... Lambertville, NJ (PRWEB) September 18, 2014 ... consulting firm, announced today that President and co-founder ... Business Journal’s Innovation Award Winners for 2014, recognizing ... naming him as an emerging executive of the ... health care and life sciences that continue to ...
(Date:9/18/2014)... 18, 2014 Stealth Health Revolution ... advocate, and Frank Davis, founder of Food for ... are pleased to announce the new recipe book, ... delicious, nutrition-packed meals using Activz whole-food powders." ... step in the Stealth Health Revolution ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... ... scores to the Centers for Medicare and Medicaid Services , ... Houston, TX (PRWEB) October 6, 2009 -- ... beneficiaries in the counties of Harris, Fort Bend, Montgomery, and Galveston on the Mainland, ...
... , New National Survey Finds Jobless Individuals Four Times ... 6 A new national survey shows the economic downturn is ... who are unemployed are four times as likely as those with ... Americans who experienced involuntary changes in their employment status, such as ...
... Oct. 6 iJET Intelligent Risk Systems, a ... services, today announced the third webinar in its ... Resiliency." These interactive webinars help multinational organizations institute ... their organizations, especially amidst the ongoing effects of ...
... ... gathered recently at the Massachusetts Institute of Technology,s Faculty Club for ... being used to save lives, reduce suffering and extend human potential. ... by Alexander Medvedev, PhD., Vice President, Research & Development, Terumo Heart, ...
... bioTheranostics, a bioMerieux company that discovers, develops and commercializes ... company has signed a two-year agreement with Lab21 to ... in the United Kingdom (UK), Ireland and Middle East ... the terms of the agreement, UK-based Lab21 will market ...
... ... the parts washing industry. Midbrook has extensive experience washing parts and equipment in a variety ... facility to help a North American automotive parts supplier solve a de-rusting issue. , ... (Vocus) October 6, 2009 -- ...
Cached Medicine News:Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 3Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 2Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 3Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 3Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 2Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 3Health News:Midbrook Production Washing A Valuable Partner 2Health News:Midbrook Production Washing A Valuable Partner 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: